Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria

Autor:	Günter Henze, Gabriele Calaminus, Martin Zimmermann, Willi Woessmann, A von Stackelberg, Helmut Gadner, Heribert Juergens, Christine Mauz-Koerholz, Georg Mann, Norbert Graf, Martin Schrappe, Birgit Burkhardt, Stefan Rutkowski, Claudia Rossig, Uta Dirksen, Dirk Reinhardt, Günther Schellong, Peter Kaatsch, Anja Moericke, U. Creutzig, Frank Berthold, Stefan S. Bielack
Rok vydání:	2013
Předmět:	medicine.medical_specialty Pediatrics business.industry Childhood cancer Hematology Pediatric cancer Clinical trial Oncology Interim Scale (social sciences) Pediatrics Perinatology and Child Health Treatment intensity medicine Overall survival Tumor board Intensive care medicine business
Zdroj:	Pediatric Blood & Cancer. 60:1574-1581
ISSN:	1545-5009
DOI:	10.1002/pbc.24598
Popis:	In Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease-specific first-line clinical trials or interim registries. Essential components are a pediatric cancer registry and centralized reference laboratories, imaging review, and tumor board assistance. The five-year overall survival rate in countries where such infrastructures are established has improved from 80% since 1995. Today, treatment intensity is tailored to the individual patient's risk to provide the highest chances of survival while minimizing deleterious late effects. Multicenter clinical trials are internationalized and serve as platforms for further improvements by novel drugs and biologicals.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::81cb16adcee71be96b85f5fe4a753fb6 https://doi.org/10.1002/pbc.24598 Zobrazit plný text záznamu Plný text